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Abstract
Background: Clinical trial participation, especially among cancer clinical trials in adult
populations, continues to be low despite the large number of clinical trials available across the
U.S. Estimates for clinical trial participation are as low as 5% in some adult cancer populations,
however in some lymphoma populations this figure may be as high as 13.9%. This figure can be
confusing, given that as much as 70% of Americans are estimated to be willing to participate in
a clinical trial. Previous research shows that as much as 95% of surveyed respondents who said
they had previously participated in a clinical trial stated they would consider future
participation in another clinical trial. Goals and Objectives: This study contains four primary
objectives. The first is to provide descriptive statistics for the Nebraska Lymphoma Study Group
(NLSG) study population at the University of Nebraska Medical Center (UNMC). The second is to
determine associations between demographic and clinical variables and two separate outcome
variables: participation in the NLSG study and participate in a clinical trial as front-line therapy.
The third objective is to determine the association between participation in the NLSG study and
participation in a clinical trial as front-line therapy. The fourth objective is to develop a logistic
regression model for participation in a clinical trial as front-line therapy. We hypothesize that
patients who agree to participate in the NLSG study will be more likely to select a clinical trial as
front-line therapy. Methods: Demographic and clinical information were provided from the
NLSG research team at UNMC. Tests for association between categorical variables and two
separate outcome variables, participation in the NLSG study and participation in a clinical trial
as front-line therapy, were examined using Chi-square analyses. An odds ratio was calculated
for participation in the NLSG study and participation in a clinical trial as front-line therapy.
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Logistic regression analysis among bivariate predictor variables was modeled for the outcome
of participation in a clinical trial as front-line therapy. Results: The sample population consisted
of N=2,343 patients. Ethnicity as a multivariate categorical variable and ethnicity as a bivariate
categorical variable (White, non-Hispanic and all other ethnicities) were significantly associated
with participation in the NLSG study (p=0.007 and p<0.001, respectively). N=125 patients
selected a clinical trial as front-line therapy. Age at diagnosis was found to be negatively
associated with participation in a clinical trial as front-line therapy (p=0.006). Those who
participated in a clinical trial as front-line therapy had 3.48 times the odds of previously
participating in the NLSG study, however this was not statistically significant (95% CI=0.47,
25.35). A logistic regression model for selection of a clinical trial as front-line therapy was
developed which included two significant covariates, age at diagnosis and diagnosis type. The
logistic regression model showed that those who were younger (below the median age at
diagnosis) and those with Hodgkin lymphoma diagnosis were at greater odds of selecting a
clinical trial as front-line therapy. Conclusions: We found that ethnicity, in particular those who
were White, non-Hispanic were more likely to have been enrolled in the NLSG study.
Additionally, we found that those who were younger (below the median age at diagnosis of 57
years), and those with a diagnosis of some subtype of Hodgkin Lymphoma, were more likely to
have selected a clinical trial as front-line therapy. We found that those who chose a clinical trial
as front-line therapy were at 3.48 times the odds of having previously agreed to participate in
the NLSG study, however this association was not statistically significant. We recommend that
further research be done to investigate the factors associated with registry and clinical trial
participation among non-White ethnic groups as well as among older populations. We also
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recommend that future similar research be done on lymphoma populations in other geographic
areas in the U.S. as well as in other disease states or health conditions to examine predictive
factors for participation in clinical trials. Understanding factors that positively influence clinical
trial participation may improve clinical trial participation rates.
Key Words & Phrases: Lymphoma, Predictive Factors, Registry, Clinical Trial, Logistic Regression,
Nebraska Lymphoma Study Group, Clinical Trial Participation
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Service Learning
Service Learning Placement Site
The placement site for the student’s Service Learning experience was the Fred & Pamela
Buffett Cancer Center (FPBCC) at the University of Nebraska Medical Center (UNMC), located in
Omaha, Nebraska. UNMC the only public academic health science center in the state of
Nebraska. The university is committed to research aimed at finding cures for a wide variety of
diseases, to providing the best possible care for its patients, and to serving the state and its
communities through award-winning outreach programs (UNMC, 2018). The mission of UNMC
is, “to lead the world in transforming lives to create a healthy future for all individuals and
communities through premier educational programs, innovative research and extraordinary
patient care” (UNMC, 2018). The FPBCC is the only cancer center in Nebraska with the National
Cancer Institute (NCI) designation and is one of 69 NCI-designated centers in the U.S.
Additionally, it is a founding member of the National Comprehensive Cancer Network (NCCN),
which is an alliance of 19 cancer centers across the world that contributes towards the
development of standards and guidelines for the treatment of cancer patients. For over 40
years, the FPBCC has been a leader in the fight against cancer. Physicians and research
scientists at the FPBCC collaborate in translational research efforts, which offers their patients
the most recent, cutting-edge therapies in their fight against cancer. (UNMC, 2018).
Service Learning Activities
The service learning component of the project focused on the development of a rapid
autopsy and tissue banking program, “Fighting Cancer After Death (FCAD): A Postmortem
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Tissue Banking Program from Patients with Hematologic Malignancies”. Activities that were
performed include an extensive literature review on rapid autopsy programs (RAP) across the
U.S and Europe, collaboration with pancreatic cancer researchers who have an established RAP
to develop standard operating procedures for pre-, during-, and post-autopsy checklists,
creation and submission of a complete institutional review board (IRB) application and
informed consent form (ICF) for the RAP, development of patient-friendly informational
pamphlets regarding tissue donation, and creation of a database for linking of clinical data to
tissue samples.
Service Learning Goals and Objectives
1. Perform an extensive literature review of rapid autopsy programs in the United
States and Europe and collaborate with pancreatic rapid autopsy program (PRAP)
investigators to review features of established programs.
2. Develop standard operating procedures that will guide the conduct of a tissue bank
for postmortem tissue donation from patients with hematologic malignancies.
3. Start and complete a full institutional review board (IRB) application and informed
consent form (ICF) for submission to UNMC’s IRB.
4. Create a database for linking relevant clinical data to tissue sample donations
Capstone Experience Goals and Objectives
The dataset from the NLSG, established by Dr. James O. Armitage in 1982, will serve as
the sample population from which statistical analyses will be performed. The NLSG has tracked
thousands of patients with hematologic malignancies, particularly Hodgkin’s Disease (HD), non7

Hodgkin’s Lymphoma (NHL), and other hematologic disorders for several decades; the
investigators and supportive staff have collected extensive data in regards to patients’
diagnoses, pathological tissue samples, demographics, and treatment regimens. The key
objectives for the capstone experience are listed below.
1. Report descriptive statistics such as demographic information, type of malignancy,
prior treatments and other relevant clinical data, as appropriate, and conduct
comparative analyses on patients enrolled in the Nebraska Lymphoma Study Group
(NLSG) database. We hypothesize that those who select a clinical trial as front-line
therapy will have greater odds of previously agreeing to participate in the NLSG
study.
2. Develop a logistic regression model from the NLSG database from significant
covariates for prediction of participation in a clinical trial as front-line therapy.
Introduction & Background
General Cancer Statistics
According to the National Cancer Institute (NCI), in 2018 there will be an estimated
1,735,350 incident cancer cases in the U.S. and about 609,640 people will die from cancer (NCI,
2018). Some of the most common forms of cancer include breast, lung and bronchus, prostate,
colorectal, melanoma, bladder, non-Hodgkin lymphoma, among others (NCI, 2018). When
looking at men and women combined, the total cancer incidence rate is 439.2 per 100,000 and
cancer mortality rate is 163.5 per 100,000, based on 2011-2015 data (NCI, 2018). The estimated
number of people living with cancer is expected to grow significantly over the next decade. The
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NCI estimates there were 15.5 million people living with cancer in 2016, and that figure is
estimated to grow to 20.3 million by the year 2026 (NCI, 2018). The burden of cancer is high
among U.S. populations. Based on 2013-2015 data, nearly 2 in 5 people living in the U.S.
(38.4%) will be diagnosed with cancer at some point in their life (NCI, 2018). Cancer also creates
a massive national economic burden in the U.S. The NCI’s Cancer Trends Progress Report,
“Financial Burden of Cancer Care”, estimates that the national expenditures for complete
cancer care, which accounts for those diagnosed with cancer, their families, and society as a
whole, was $137.4 billion in 2010 and has grown to $147.3 billion in 2017 (NCI Cancer Trends
Progress Report, 2018).
Hematologic Cancer Statistics
The Service Learning section of this project aimed to develop a rapid autopsy program
(RAP) for patients with hematologic malignancies including lymphoma, leukemia, and multiple
myeloma. Lymphoma is a term that encompasses cancers that originate in lymphocytes (B- or
T-cells), which are disease-fighting cells that are a part of the lymphatic, or immune, system
(NCI, 2015).
Lymphoma. Lymphoma is grouped into two main types: non-Hodgkin Lymphoma (NHL)
and Hodgkin Lymphoma (HL). In 2015, which is the most recent year for which incidence data
are available, there were 67,522 new cases of NHL and 20,154 deaths in the U.S. (CDC Data
Visualizations, 2015). There were roughly 18 new cases of NHL reported per 100,000 persons in
the U.S. The lifetime risk of developing NHL, based on 2013-2015, data is approximately 2.1%
for men and women combined (NCI, 2015). The most recent prevalence estimates for NHL

9

show that there are roughly 686,024 people living with NHL in the U.S. (NCI, 2015). According to
the National Cancer Institutes, based on SEER 18 data from 2008-2014, the estimated five-year
survival rate for NHL diagnoses is 71.4% (NCI, 2015). The survival rate varies by stage. For stage
I, five-year survival rate is 81.8%, II is 75.3%, III is 69.1%, IV is 61.7%, and unknown stage is
76.5% (NCI, 2015).
Hodgkin’s Lymphoma. Hodgkin’s Lymphoma is less common than NHL. In 2015, there
were 8,332 new cases of HL and 1,120 deaths in the U.S. (CDC Data Visualizations, 2015). There
were about 3 new cases of HL reported per 100,000 persons. The lifetime risk of developing HL,
based on 2013-2015 data, is approximately 0.2% for men and women combined (NCI, 2015).
The most recent prevalence estimates for HL show that there are roughly 208,805 people living
with HL in the U.S. (NCI, 2015). The estimated five-year survival rates for HL diagnoses, based
on SEER 18 data from 2008-2014, is 86.6%. Interestingly, when five-year survival rate is broken
down by stage at diagnosis, stage II has the best survival rate of 92.3%, followed by stage I
(92.3%), stage III (83.0%), and stage IV (72.9%); unknown stage has a survival rate of 82.7%
(NCI, 2015).
Leukemia. Leukemia is a type of cancer that originates in tissues of the bone marrow
that facilitate blood cell formation. These abnormal cells do not form solid tumors, but rather
accumulate in the blood and bone marrow, which may take up space for normal blood cells
(NCI, 2015 (1)). The four most common groups of leukemia are based on how the rate at which
the disease worsens (acute or chronic) and on the type of blood cell in which the cancer
originates (lymphoblastic or myeloid) (NCI, 2015). In 2015, there were 47,601 new cases of
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leukemia and 22,847 deaths in the U.S. (CDC Data Visualizations, 2015). There were roughly 13
new cases of leukemia reported per 100,000 persons.
Multiple Myeloma. A type of cancer that originates in plasma cells, cells that develop
from B-cells that assist in antibody production, is referred to as multiple myeloma (NCI, 2015)
or plasma cell myeloma. Myeloma cells, otherwise known as abnormal plasma cells,
accumulate in the bone marrow. Multiple myeloma tumor formation occurs in bones
throughout the entire body. In 2015, there were 24,265 new cases of multiple myeloma and
12,231 deaths in the U.S. ((CDC Data Visualizations, 2015). There were 6 new cases of multiple
myeloma reported per 100,000 persons.
Lymphoid Cell Differentiation and Tissue Analysis
Immune cells develop through a complex process of differentiation starting from
hematopoietic stem cells (HSC), yielding multiple myeloid and lymphoid cell types that can
differentiate and polarize towards distinct subtypes. Different hematologic malignancies can be
aligned with “normal counterparts” within the immune system based upon histologic and
immunophenotypic characteristics. For example, B-cell lymphomas are characterized according
to their alignment with distinct stages of B-cell development. Marginal zone lymphoma (MZL)
aligns with marginal zone B-cells, mantle cell lymphoma (MCL) aligns with mantle zone B-cells,
and multiple subtypes including follicular lymphoma (FL), Burkitt lymphoma (BL) and diffuse
large B-cell lymphoma (DLBCL) align with the germinal center B-cell stage of development
(Kuppers, 2005). Patterns of genomic evolution in common B-cell malignancies have been
characterized (Green et al., 2015; Green et al., 2014) and modeled the stepwise acquisition of
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genetic alterations that give rise to this disease. However, it remains unknown whether specific
lymphoid malignancies align with discrete stages of differentiation because that is the stage at
which they acquired the transforming genetic event, or because the transforming event drives
alterations in cell differentiation. In order to address this question, each stage of lymphoid
differentiation will need to be analyzed at high resolution with sufficient sample volume to
capture rare events; this will require the acquisition of tissues from multiple sites, including
hematopoietic stem cells from the bone marrow, as well as nearby normal tissue counterparts
from the same patients.
Service Learning Background
There is a lack of postmortem tissue banking services for hematologic malignancies,
especially in adult populations across the United States. The Service Learning component of the
student’s project aimed to develop policies and procedures for the rapid obtainment of tissue
from patients who have died from hematologic malignancies for use in basic science research,
as well as to develop a clinical database for capturing clinical and pathological data. The
Capstone Experience component of the student’s project aimed to provide descriptive statistics
on patients enrolled in the Nebraska Lymphoma Study Group (NLSG) Registry & Tissue Bank
Study, significant associations for participation in the NLSG Registry & Tissue Bank Study and for
participation in a clinical trial as front-line therapy, and a predictive logistic regression model for
clinical trial participation as front-line therapy.
The tissue collected from the “Fighting Cancer After Death” study will be stored in the
Lymphoma Precision Medicine Tissue Bank, which is part of the James O. Armitage Center for
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Leukemia and Lymphoma Research at the University of Nebraska Medical Center. The purpose
of this study is to rapidly obtain tissue from patients who have died from hematologic
malignancies for use in basic science research. It is essential to procure these tissues within a
few hours of death due to rapid destruction of the tissue by enzymes. Defining the
premalignant compartments in hematologic malignancies will allow strides forward in the
treatment of this disease. In many cases, complete response can be achieved following
treatment of these malignancies; however, most patients ultimately relapse and show diverse
patterns of genomic evolution. This suggests that premalignant compartments that possess
only a subset of the oncogenic events that are detected in the clinically evident tumor
propagate relapses. By identifying the oncogenic events in separate compartments (marrow,
lymph node, or organ), tissue available from this project may be able to develop research
strategies to better characterize this process.
Factors Associated with Participation in Registry Studies
Outcome, a Quintiles company, in their 2012 report “Standards in the Conduct of
Registry Studies for Patient-Centered Outcomes Research”, prepared for the methodology
committee of the Patient-Centered Outcomes Research Institute (PCORI), defined a patient
registry as “an organized system that uses observational study methods to collect uniform data
(clinical and other) to evaluate specified outcomes for a population defined by a particular
disease, condition or exposure, and that serves one or more predetermined scientific, clinical,
or policy purposes” (Gliklich et al., 2012; Gliklich et al., 2010). Registries serve as important
sources of data for patient-centered outcomes research (PCOR), especially those that enroll
patients with specific diseases or those who have exposure to specific treatments or other
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therapies (Dreyer & Garner, 2009; Dreyer et al., 2010). Registries provide the opportunity to
study populations that may not typically be enrolled in standard clinical trials such as children,
elderly, those with multiple or severe comorbidities in addition to the clinical data that are of
importance to investigators and potentially the patients themselves. Factors for participation in
registry studies, specifically factors that are positively associated with participation, as well as
barriers for participation, vary depending on the disease of interest.
A survey by Solomon et al. examined the patients’ experience between two chronic
disease registries, one focused in rheumatoid arthritis (RA) and another in inflammatory bowel
disease (IBD). Among 150 completed surveys from the RA registry and 169 from the IBD
registry, the top three factors for participation in the registries were very similar. These factors
were the desire to help others, the desire to improve care of their own disease, and the ease of
volunteering (Solomon et al., 2017). The investigators made several key conclusions from their
results. The first of which was that successful recruitment of patients to participate in a registry
study likely depends on the appeal to altruism. Many patients responded that their willingness
to participate was based on a desire to help others as well as the potential of improved care for
their own disease. A second factor, the ease of participation, was noted among respondents.
The surveys were easy and quick to complete, which was favorable for participants, especially
those who were older (Solomon et al., 2017).
Another type of registry that is becoming increasingly more common in the U.S. is donor
programs. A 2013 study by Switzer et al., examined race and ethnicity as factors for unrelated
hematopoietic stem cell (HSC) donation. The donor program that was examined was the
National Marrow Donor Program (NMDP), which is the largest registry in the world that focuses
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on matching unrelated donors with patients that are in need of an HSC transplant; the NMDP
has assisted in over 50,000 successful transplantations from its unrelated donor program in its
25-year history (Switzer et al., 2013). Despite the fact that the NMDP has more than 10 million
registrants and that thousands of new volunteers are signing up each month, the NMDP and
similar registries across the world experience difficulties in identifying matched donors for
certain populations, particularly racial and ethnic minorities (Dehn et al., 2008). Additionally,
according to NMDP program statistics, donor attrition rates within the NMDP registry are much
higher for racial and ethnic minority groups when compared to non-minority groups (about
60% compared to 40%), and reasons for this disparity in attrition rates remains unanswered.
(Switzer et al., 2013). Significant factors for attrition included patients’ doubts and worries,
feeling unsure about donation, and hoping that someone else would donate instead of them
(Switzer et al., 2013). As we are going to assess the relationship between participation in a
registry study and participation in a clinical trial as front-line therapy, it is important to
understand factors that are associated with clinical trial participation.
Factors Associated with Participation in Clinical Trials
Clinical trial participation, especially in cancer clinical trials in adult populations,
continue to be low despite the large number of clinical trials available across the U.S. Some
studies estimate that fewer than 5% of adult cancer patients will enroll in a cancer clinical trial
(Murthy, Krumholz, & Gross, 2004; Tejeda et al., 1996). However, this figure may be higher in
lymphoma populations. The National LymphoCare Study, which was conducted as a
multicenter, prospective, observational study examined treatment regimens and associated
outcomes among N=2,728 follicular lymphoma patients. The investigators for this study
15

reported that 13.9% of patients participated in a clinical trial as front-line therapy (Friedberg et
al., 2009). This figure can be confusing, especially when considering that as much as 70% of
Americans are estimated to be willing or inclined to participate in a clinical trial (Comis et al.,
2003). Barriers that have been previously researched include structural (clinic access), clinical
(patient eligibility), behavioral (physician’s decision to discuss trial with a patient and whether
or not the trial is offered; patient’s decision to enroll, if offered), demographic, and
socioeconomic (Unger et al. 2017).
A retrospective chart review study, conducted from 14 years of patient data, analyzed
sociodemographic, clinicopathologic, and treatment characteristics of 558 advanced-staged
ovarian cancer patients that were treated at a single institution at one point. Seventy one
percent (339/558) of patients did not participate in a clinical trial. Of those that did participate,
the majority (78.75%) participated at the time of recurrence. Factors that were significantly
associated with clinical trial participation included younger age (58 years v. 63 years, p <
0.0001), type of insurance (p < 0.0001), receipt of neoadjuvant chemotherapy treatment (p =
0.014), and gynecologic oncologist as adjuvant chemotherapy treatment provider (p = 0.005)
(Mallen et al., 2018). Factors that were not significantly associated with clinical trial
participation include race, educational level, religion, marital status, and distance traveled for
care.
Another investigation into patient participation in clinical trials listed lack of awareness
about clinical trials, assumptions about their eligibility, afraid of the unknown outcome of a
clinical trial, and confusion regarding insurance as factors for why patients do not participate
(Lopienski, 2014). Factors that were in favor of clinical trial participation included an altruistic
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attitude towards the advancement of medical knowledge among 86% of surveyed patients,
access to promising treatments (89% of respondents), recommendation from a trusted person
such as their doctor, a family member or friend, and if they had a previous positive experience
with a clinical trial (Research!America, 2013) Previous experience in a clinical trial was shown to
be a very significant factor; 95% of respondents who said they had previously participated in a
clinical trial stated that they would consider future participation in another clinical trial (CISCRP,
2013).
A prospective patient survey among Gastrointestinal and Lymphoma Unit patients at the
Royal Marsden specialty cancer center in the United Kingdom was conducted between August
2013 and July 2014 to examine patients’ willingness to participate in clinical trials and their
overall views on certain aspects of cancer research. The most frequent answers in response to
the main reason for trial participation were “the trial offered the best treatment available” and
“the trial results could benefit others” (Moorcraft et al., 2016). Interestingly, age played a factor
in the sense of altruism of the participants. Patients that were less than 65 years of age were
more likely to state that their primary reason for participation was “the trial results could
benefit others” when compared to those greater than or equal to 65 years of age (64%
compared to 39%, OR = 2.77 (1.62-4.74), p < 0.001). Additionally, those who had participated
previously in a clinical trial (72%) compared to those who had not (50%) were more likely to
state an altruistic reason for their participation (OR = 2.65 (1.21-5.83), p = 0.012). Factors that
were found not to be statistically significant included gender and the total number of previous
treatment regimens. There were also several interesting results regarding patients’ views on
cancer research and biopsies. Of the patients who completed the first questionnaire, 96%
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reported that they were happy having been approached to participate in cancer research and
99% believed that cancer research would help future physicians and investigators better
understand and treat cancer (Moorcraft et al, 2016). The majority of patients (74%) disagreed
or strongly disagreed with the statement: “I have concerns about the use and storage of blood
and tissue samples for research”. Perhaps most importantly, in terms of future tissue donation,
78% of patients agreed or strongly agreed and another 11% were neutral in regards to the
statement: “I would agree to donate tissue for genetic research even if I was not told my
genetic results” (Moorcraft et al., 2016).
Overview Rapid Autopsy Programs
Rapid autopsy technology and programs have been available for physicians and
researchers for several decades. A group of researchers at the University of Washington have
been using rapid autopsy technology to investigate prostate cancer since 1991, and the
University of Nebraska Medical Center’s pancreatic rapid autopsy program (PRAP) was
established in 2002. In a Kaiser Health News article published in April, 2018, Dr. Jody Hooper,
the director of the Legacy Gift Rapid Autopsy Program at Johns Hopkins University in Baltimore,
Maryland, estimated that there are currently 14 similar autopsy programs in the U.S. (KHN,
2018). This figure shows that the launch of new programs has been slow over the past two or
three decades. The value of rapid autopsy programs is massive, especially in cases where the
disease has metastasized to several distant locations, sometimes locations that are difficult or
impossible to reach in a living patient. These tissue samples, possibly obtained from all over the
patient’s body, are able to be quickly frozen or fixed in other preserving methods; these
samples are then able to be accessed in the future by investigators looking to conduct research
18

on these cancer tissues. Rapid autopsy programs may also be expanded to other diseases, such
as HIV and other diseases where viruses other pathogens may hide throughout the body (KHN,
2018). To date, there are no rapid autopsy programs in the U.S. solely dedicated to patients
with hematologic malignancies.
Factors Associated with Tissue Donation
Research has shown that postmortem tissue donation may be a positive opportunity not
only for investigators, but also for the families of deceased patients. A two-year pilot project in
multiple sclerosis showed that, of families that authorized the donation of tissue samples for
research, the respondents to a short questionnaire indicated that they were not further
distressed by the approach, and the majority were of the opinion that research donation should
be offered to all bereaved families (Millar et al., 2008). Other research has shown that there are
other forms of obtaining informed consent by either the patient, while still alive, or family
members of the deceased. A prospective, comparative cross-sectional study in Spain by
Rodriguez-Villar was performed that included telephone interviews during the tissue donation
application process. Of the potential donors, 29% (222/770) of interviews were held over the
phone. A positive family answer was obtained 27% of the time. Although this result was less
than that of in-person interviews, a calculated donor generation efficiency rose 16 percent to
59% when telephone interviews were added to in-person interviews (Rodriguez-Villar et al.,
2007). There are several factors that may influence the decision of patients or their families
regarding organ or tissue donation. Factors that were significantly associated with organ
donation include knowledge, attitudes, and beliefs about donation (Matten et al., 1991). Other
research showed that females, younger individuals, and those with higher knowledge levels
19

were more likely to have attitudes that favored organ donation; within that same study,
individuals who described themselves as having stronger religious beliefs and those with poor
knowledge had less favorable attitudes toward organ donation (Wakefield et al., 2011). Tandon
showed that, in a prospective study, level of literacy, socioeconomic status, and prior
knowledge of organ donation were not associated with corneal tissue procurement (Tandon et
al., 2004). A systematic review by Irving involving 18 studies and 1,019 participants showed
eight major themes regarding organ donation. The decision to be an organ donor was
influenced by relational ties, religious beliefs, cultural influences, family influences, body
integrity, previous interactions with the healthcare system such as medical mistrust, the
individual’s knowledge about the organ donation process, and major reservations about the
process of donation (Irving et al., 2011).
Despite the research highlighted above, there seems to be a lack of research on factors
associated with participation in a registry and tissue bank study in lymphoma populations,
specifically in a Midwestern metro area, as well as a lack of research on factors associated with
participating in a clinical trial as front-line therapy in lymphoma populations.
Methods
Nebraska Lymphoma Study Group
The Nebraska Lymphoma Study Group (NLSG), established in 1982, has tracked
thousands of patients with hematologic malignancies, particularly Hodgkin’s Disease (HD), nonHodgkin’s Lymphoma (NHL), and other hematologic disorders for several decades; the
investigators and supportive staff have collected extensive data in regards to patients’
20

diagnoses, pathological tissue samples, demographics, and treatment regimens. The NLSG is a
unique collaborative effort between oncologists and pathologists in the community, as well as
their colleagues at UNMC. A unique aspect of the NLSG is that the majority of the patients
enrolled in the study are previously treated and may be the most likely to benefit from the
treatment regimens offered through the study. One example of the collaborative effort
between the medical oncologists and the pathologists is that, in several cases, fresh tissue
samples are collected from the patients are delivered to the pathologists at UNMC so that they
may perform complex, detailed histopathologic, immunologic, and molecular characterization
(UNMC, 2018).
Data Delivery, Cleaning, and Manipulation
The NLSG maintains an electronic database that contains clinical, pathologic, and
genetic data on lymphoma patients as well as other patients of interest. A request for data was
submitted to the lead data coordinator for the NLSG for cases that contained basic
demographic information (sex, ethnicity, date of birth, age at diagnosis) as well as clinical and
treatment information (diagnosis, subtype, consent status to the NLSG, first line therapy
regimen, and whether first line therapy regimen was a clinical trial). Additionally, it should be
noted that the database did not capture information on whether a clinical trial was available at
the time the patient received front-line therapy. When the request for data was submitted, the
electronic database was in the midst of some technical issues. The dataset therefore only
captured cases through February 2018 that had data entered for their diagnosis. The dataset
was delivered in an Excel spreadsheet.
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Extensive data management activities, including data cleaning and data manipulation,
were conducted in Excel. Examples of data cleaning and manipulation that were performed
include running procedures in SAS to check for missing and duplicate data, as well as data that
would not make sense clinically (i.e., date of diagnosis the same as date of birth). Other data
manipulations included adding new variables (i.e., whether the diagnosis fell under nonHodgkin lymphoma, Hodgkin lymphoma, or other, and recoding age at diagnosis to round down
ages that included a decimal to the nearest whole number). All data cleaning methods, data
manipulations, and responses to data clarification requests were discussed with the lead data
coordinator for the NLSG to ensure appropriateness and accuracy before any analyses were
conducted.
Study Design
This study used the Nebraska Lymphoma Study Group Registry & Tissue Bank Study
clinical database to perform a descriptive analysis on patients enrolled in the study. In addition,
this study used case-control study design to measure the association between consent status to
the NLSG study and participation in a clinical trial as front-line therapy. Exposed individuals
were considered those who consented to the NLSG study, and unexposed individuals were
considered those who did not consent to the NLSG study (did not agree to have tissue from lab
samples, biopsy procedures, etc. to be stored) but allowed their clinical data to be followed.
The outcome of interest was selection of a clinical trial as front-line therapy (yes/no). Cases
were identified as those who selected a clinical trial as front line therapy, and controls were
identified as those who selected a front-line therapy regimen that was not considered as a part
of a clinical trial. There were 5 cases that were missing an NLSG participation status and were
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therefore not included in this analysis. Controls were selected from this sample population for a
few different reasons. The first of which was the time frame of the student’s project. As the
capstone project is conducted in one semester, the selection process of several hundred or
thousands of control patients would have been too large of a time constraint on the student’s
project. The second reason was convenience. The control data was already available in the
database that was delivered to the student.
Statistical Analysis
Data management and manipulation was conducted in Microsoft Excel software. Chisquare analyses were conducted between select covariates and two outcome variables:
participation in the NLSG registry study and participation in a clinical trial as front-line therapy.
Fisher’s Exact Test was performed when expected cell counts were less than five. The
covariates that were tested for association included sex, ethnicity, age at diagnosis, and
diagnosis class. An odds ratio calculation with a 95% confidence interval was perform to
measure the association between participation in the NLSG registry study and participation in a
clinical trial as front-line therapy. To develop the logistic regression model, odds ratio
calculations were conducted between different covariates to determine if any interactions or
confounding existed. No interactions or examples of confounding were identified. Therefore,
only significant crude odds ratios were incorporated into the logistic regression model. Only
covariates with a significant association (p < 0.05) were included in the final model. The final
logistic regression model for predicting selection of a clinical trial as front-line therapy is
reported in Table 5. SAS® 9.3 Software was used for Chi-square analyses, odds ratio calculation
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with 95% confidence interval, and logistic regression modeling. An alpha level of 0.05 was used
for significance.
Results
Descriptive Statistics
There were 2,343 patients identified in the Nebraska Lymphoma Study Group dataset.
The median age at diagnosis was 57 years (14 to 101 years) with a mean age at diagnosis of
55.2 years (+/- 17.3 years); 34 patients did not have a documented age at diagnosis. Patients
included in the NLSG dataset were diagnosed from December 1973 through February 2018.
N=1,271 (54.2%) of patients were male and N=1,072 (45.8%) were female. White, non-Hispanic
participants were the majority (N=2,144, 91.5%), followed by Black, non-Hispanic (N=86, 3.7%)
and White, Hispanic (N=36, 1.5%); N=40 observations contained a missing ethnicity (1.7%).
There were 102 distinct diagnoses included in the NLSG dataset. Some of the most
common diagnoses were: diffuse large B-cell lymphoma, noncleaved (B-DLCL-NC, N=199, 8.5%),
composite lymphoma (CL, varying percentages, N=133, 5.8%), diffuse large B-cell lymphoma,
not otherwise specified (B-DLCL-NOS, N=120, 5.1%), nodular sclerosing Hodgkin lymphoma,
grade 1 (HD-NS-1, N=102, 4.4%), B-cell chronic lymphocytic leukemia (B-CLL, N=97, 4.1%),
extranodal marginal zone B-cell lymphoma, MALT type (B-EMZL, N=97, 4.1%), and follicular
lymphoma, grade 2 (B-FL-2, N=97, 4.1%). There were N=48 observations that did not have a
diagnosis included in the dataset, and the NLSG staff could not clarify these missing data. When
encompassing all common subtypes, diffuse large cell lymphoma was the most common type of
diagnosis with N=527 cases, followed by follicular lymphoma (N=342), nodular sclerosing
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Hodgkin lymphoma (N=216), composite lymphoma (N=133), and non-Hodgkin lymphoma, not
otherwise specified (N=108).
Table 1: Demographic Information
Demographic Characteristic

N (%)

Median Age at Diagnosis (Years)

Mean Age at Diagnosis
(Years, SD)

Age at Diagnosis

2,309

57

55.2, 17.3

Male

1,271 (54.2%)

56

54.5, 16.7

Female

1,072 (45.8%)

59

56.2, 18.1

Asian

18 (0.8%)

51

50.7 (12.1)

Black, non-Hispanic

86 (3.7%)

50

49.3 (16.9)

Missing

40 (1.7%)

61

61.9 (13.5)

Other

19 (0.8%)

45

47.2 (17.9)

White, Hispanic

36 (1.5%)

44.5

44.9 (18.7)

2,144 (91.5%)

58

55.7 (6.5)

Sex

Ethnicity

White, non-Hispanic

Table 2: Diagnosis Subtypes, Listed Alphabetically by Abbreviation (N=2,343)
Diagnosis Subtype

N

%

Diagnosis Subtype

N

%

Diagnosis Subtype

N

%

B-BL

25

1.07

DL-C

9

0.38

MC

20

0.85

B-BLL

26

1.11

DL-ML

3

0.13

MF

2

0.09

B-BMCL

22

0.94

DL-NC

61

2.60

MZL

1

0.04

B-CLL

97

4.14

DL-NOS

30

1.28

NHL-NOS

80

3.41

B-DFL-1

5

0.21

DM-C/NC

4

0.17

NK/T-NL

5

0.21

B-DFL-2

6

0.26

DM-NOS

9

0.38

NK/T-PL

1

0.04

B-DLCL-AP

11

0.47

DSC

8

0.34

NOS

22

0.94

B-DLCL-C

43

1.84

FL-C

1

0.04

NS-LD

11

0.47

B-DLCL-EBV

4

0.17

FL-NC

15

0.64

NS-M1

34

1.45

25

B-DLCL-INOS

13

0.55

FM

32

1.37

NS-M2

22

0.94

B-DLCL-IP

17

0.73

FSC

22

0.84

Other

4

0.17

B-DLCL-LG

1

0.04

HD-IF

9

0.38

SL

22

0.94

B-DLCL-NC

199

8.49

HD-LD

2

0.09

SL-CLL

1

0.04

B-DLCL-NOS

120

5.12

HD-LP-N

11

0.47

SL-PC

3

0.13

B-DLCL-PB

8

0.34

HD-LR

6

0.26

SNC-B

3

0.13

B-DLCL-THR

8

0.34

HD-MC

39

1.66

SNC-NB

13

0.55

B-DMCL

35

1.49

HD-NOS

25

1.07

SUS

4

0.17

B-EMZL

97

4.14

HD-NS-1

102

4.35

T-CCD4SML

5

0.21

B-FL-1

84

3.59

HD-NS-2

29

1.24

T-EATL

2

0.09

B-FL-2

97

4.14

HD-NS-CP

15

0.64

T-HSGDL

5

0.21

B-FL-3

91

3.88

HD-NS-S

3

0.13

T-MF

3

0.13

B-LPL

16

0.68

IBL-C

4

0.17

T-PGDL

1

0.04

B-NMCL

56

2.39

IBL-E

1

0.04

T-PLL

2

0.09

B-NMZL

31

1.32

IBL-NOS

9

0.38

T-PTCL-AI

15

0.64

B-PLL

1

0.04

IBL-P

10

0.43

T-PTCL-LC

15

0.64

B-SLL

71

3.03

IBL-P/A

4

0.17

T-PTCL-LE

2

0.09

B-SMZL

11

0.47

IBL-PC

23

0.98

T-PTCL-MC

19

0.81

B-UCL

16

0.68

LB-C

7

0.30

T-PTCL-UC

10

0.43

B-UCL-HD

5

0.21

LB-NC

2

0.09

T-SPTL

1

0.04

B-UCL-HG

14

0.60

LD-R

2

0.09

T/N-ALCL

10

0.43

B-UCL-LG

15

0.64

LP-D

1

0.04

T/N-ALCL-ALK

3

0.13

BP-ALL

25

1.07

LP-N

6

0.26

T/N-ALCL-NEG

8

0.34

BP-LBL

4

0.17

MALT

7

0.30

TP-ALL

9

0.38

133

5.67

MB

5

0.21

TP-LBL

12

0.51

Unknown

48

2.05

CL

The most common front-line therapy regimens were R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone; N=457, 19.5%), CNOP
(cyclophosphamide, mitoxantrone, vincristine, and prednisone; N=168, 7.2%), ABVD
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(doxorubicin, bleomycin, vinblastine, and dacarbazine; N=135, 5.8%), non-anthracyclinecontaining regimen, not otherwise specified (N=122, 5.2%), and rituximab (N=113, 4.8%). Other
options besides chemotherapy were offered to the patients as well. Radiation therapy for NHL
patients was selected in N=122 (4.8%), and radiation therapy for HL patients was selected in
N=38 (1.6%). Some patients did not require immediate treatment at the time of their diagnosis.
“Watch and Wait” was chosen for N=299 (12.8%) of patients.
Tests for Association
Two thousand, one hundred and one patients (N=2,101; 89.7%) provided consent to the
NLSG study, N=234 (9.9%) did not provide consent but agreed to have their clinical data be
followed, and N=8 (0.3%) had a missing consent status and were therefore not included in the
analysis. Sex, ethnicity, age at diagnosis, and diagnosis class were tested for association among
participation in the NLSG study using Chi square analysis. Ethnicity (all ethnicities, X2=14.02,
p=0.007) and Ethnicity (White, non-Hispanic and all others, X2=11.09, p<0.001 ) were found to
be significantly associated with participation in the NLSG study.
Table 3: Tests for Association between Select Covariates and Participation Status in the NLSG Study (N=2,335)
Covariate

Chi-Square Statistic

p-value

Sex

0.16

0.687

Ethnicity1

14.02

0.007

Ethnicity2

11.09

<0.001

Age at Diagnosis3

2.04

0.152

Diagnosis Type4

0.23

0.898

Diagnosis Type5

0.09

0.758
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1All

ethnicities (5 levels; missing ethnicity was not included in the analysis); 2White, non-Hispanic compared to all other ethnicities; 3At or above

median age (57 years) compared to below median age; 4NHL, HL, Other (3 levels); 5NHL, HL

One hundred twenty five patients (N=125, 5.3%) patients chose a treatment regimen
that was coded as a clinical trial for their front-line therapy, and N=1,919 (81.9%) did not.
“Watch and Wait” selections were excluded from this analysis. The same covariates as above
were tested for association among participation in a clinical trial as front-line therapy using Chi
square analysis. Age at diagnosis (X2=7.37, p=0.006) was significantly associated with the
selection of a clinical trial as front-line therapy.
Table 4: Tests for Association between Select Covariates and Selection of Clinical Trial as Front-Line Therapy Status
in the NLSG Study (N=2,044)
Covariate

Chi-Square Statistic

p-value

Sex

0.02

0.881

Ethnicity1

2.58

0.629

Ethnicity2

0.29

0.585

Age at Diagnosis3

7.37

0.006

Diagnosis Type4

5.75

0.056

Diagnosis Type5

5.76

0.016

1All

ethnicities (5 levels; missing ethnicity was not included in the analysis); 2White, non-Hispanic compared to all other ethnicities; 3At or above

median age (57 years) compared to below median age; 4NHL, HL, Other (3 levels); 5NHL, HL

An odds ratio calculation was conducted between two bivariate categorical variables:
participation in the NLSG study and selection of clinical trial as front-line therapy. Exposed
individuals were considered those who consented to the NLSG study, and unexposed
individuals were considered those who did not consent to the NLSG study (did not agree to
have tissue from lab samples, biopsy procedures, etc. to be stored) but allowed their clinical
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data to be followed. The outcome of interest was selection of a clinical trial as front-line
therapy (yes/no). Cases were identified as those who selected a clinical trial as front line
therapy, and controls were identified as those who selected a front-line therapy regimen that
was not considered as a part of a clinical trial. There were 5 cases that were missing an NLSG
participation status and were therefore not included in this analysis. Controls were selected
from this sample population for a few different reasons. The primary reason was the time
component of the student’s Capstone Experience project. In a classical case-control study
design in the context of cancer populations, we would ideally use individuals with cancer
diagnoses as “cases” and those without cancer diagnoses as “controls”. As the NLSG study does
not maintain an active list or subset of controls for its patients, the student would have had to
submit a full IRB application to search UNMC medical records for appropriate controls. The
student was limited by the semester parameters, and therefore this would not have been
achievable. “Watch and Wait” selections were omitted from this analysis. Those who selected a
clinical trial as front-line therapy were 3.48 times the odds to have previously agreed to
participate in the NLSG study, however this result was not statistically significant (OR=3.48;
0.47, 25.35).
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Table 5: Two-by-Two Table for Odds Ratio Calculation between NLSG Study Participation and Selection of Clinical
Trial as Front-Line Therapy
Cases

Controls

(Clinical Trial as Front-Line

(Clinical Trial as Front-Line

Therapy – Yes)

Therapy – No)

(Column %)

(Column %)

(Row %)

(Row %)

Exposed

119

1,982

(Nebraska Lymphoma Study

(99.1%)

(97.1%)

Group – Yes)

(5.6%)

(94.4%)

Unexposed (Nebraska

1

58

Lymphoma Study Group – No)

(0.9%)

(2.9%)

(1.7%)

(98.3%)

120

2,040

Totals

Totals

2,101

59

2,160

Logistic Regression Model
Odds ratio calculations were conducted between different covariates to determine if
any interactions or confounding existed. No interactions or examples of confounding were
identified. Therefore, only significant crude odds ratios were incorporated into the logistic
regression model. Age at diagnosis, categorized into “at or above median age at diagnosis” and
“below median age at diagnosis” (OR=0.6; 0.41, 0.87), and diagnosis type categorized into
“non-Hodgkin’s lymphoma” and “Hodgkin’s lymphoma” (OR=0.58; 0.37, 0.91) were
independently associated with the outcome of selection of a clinical trial as front-line therapy.
The final logistic regression model for predicting selection of a clinical trial as front-line therapy
is reported in Table 5.
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Table 5: Logistic Regression Model for Predicting Selection of a Clinical Trial as Front-Line Therapy in Patients
Enrolled in the Nebraska Lymphoma Study Group Study
ln(odds) = -2.8051 + 0.2121*(Median Age at Diagnosis) + 0.1676*(Diagnosis Type)

Median Age at Diagnosis is coded as: At or Above Median Age at Diagnosis = (-1); Below Median Age at Diagnosis = (1); Diagnosis Type is coded
as: non-Hodgkin’s lymphoma = (-1); Hodgkin’s lymphoma = (1)

Discussion
This study provided comprehensive descriptive statistics on patients enrolled in the
NLSG study. Additionally, front-line therapy regimens, as well as whether those regimens were
a part of a clinical trial, were examined in detail. An odds ratio was reported between two
bivariate categorical variables: participation in the NLSG study, and selection of a clinical trial as
front-line therapy. Lastly, a logistic regression model for predicting participation in a clinical trial
as front-line therapy was developed. It is interesting to note that White, non-Hispanic patients,
when compared to all other ethnicities were more likely to have participated in the NLSG study.
One reason that may explain this result is that the state of Nebraska, as well as the sample
population for this study, is overwhelmingly White (91.5% in this study). Also, decades of
research on different ethnic populations show that persons who are White may have higher
levels of education, higher socioeconomic status, and tend to have higher rates of insured
persons, all of which may positively influence their decision to seek care at UNMC and
participate in studies outside of their regular care. We also found that those who were of
younger age, defined as below the median age at diagnosis of 57 years, were more likely to
participate in a clinical trial as front-line therapy. One possible explanation of this result is that
younger individuals may be more willing to take a chance on an unapproved treatment
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regimen, in the hopes that it may have a better chance at curing their cancer or extending their
life expectancy. Older populations may opt more for approved treatment regimens to treat
their cancer for their front-, second-, or third-line therapies. It is possible that once older
populations have exhausted approved their therapy options that they may shift their focus on
palliative care rather than participating in a clinical trial with unknown adverse event and
response data. One final observation of interest was that those with Hodgkin lymphoma were
more likely to participate in a clinical trial as front-line therapy. It is possible that those with HL
were more likely to participate in a clinical trial as front-line therapy due to more availability of
clinical trials at their time of diagnosis, however we do not have information to assess this
possibility. Another possible reason for this difference is that the clinical trials that were
available at the time of diagnosis could have been showing promising results and were
therefore recommended by the treating physician. The dataset for this study did not include
data on the number of clinical trials that were available or the number of FDA-approved
therapies for NHL or HL at the time of diagnosis for each patient. It is possible that the number
of clinical trials and number of approved therapies fluctuated throughout the recruitment
period for the NLSG study, which therefore may affect the likelihood of selection of a clinical
trial or approved therapy. We recommend that the landscape of available therapies, both
standard of care and experimental, be documented so that this may be adjusted for in future
studies.
Conclusions
This study aimed to provide comprehensive descriptive statistics on the participants
included in the Nebraska Lymphoma Study Group Registry & Tissue Bank study, to examine
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associations between selected demographic and clinical variables and two key outcome
variables, and to develop a predictive logistic regression model for selection of a clinical trial as
front-line therapy. This study addressed the lack of research performed on factors that are
associated with participation in a registry and tissue bank study, as well as selection of a clinical
trial as front-line therapy, in a large lymphoma population enrolled at an academic medical
center located in Omaha, Nebraska.
We found that participants who were White, non-Hispanic were more likely to have
agreed to participate in the NLSG study when compared to all other ethnicities. We also found
that participants who were below the median age of 57 years were more likely to select a
clinical trial as front-line therapy. Lastly, we found that those who selected a clinical-trial as
front-line therapy were 3.48 times the odds of previously agreeing to participate in the NLSG
study, however this result was not statistically significant; a logistic regression model using two
significant covariates, age at diagnosis and diagnosis type, was developed for predicting
selecting a clinical trial as front-line therapy. The dataset used in this study was graciously
provided by the NLSG study staff. All data management activities, including clarifications on
ambiguous data, re-coding of select variables, and creation of new variables from the existing
data were discussed with and confirmed by the lead data coordinator for the NLSG study. Chisquare tests for association between select covariates and two outcome variables, participation
in the NLSG study and selection of a clinical trial as front-line therapy, were performed. An odds
ratio was calculated for the association between participation in the NLSG study and selection
of a clinical trial as front-line therapy; the results showed that those who selected a clinical trial
as front-line therapy were at nearly 3.5 times the odds of previously participating in the NLSG
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study, however this result was not statistically significant. Lastly, a predictive logistic regression
model was developed for selection of a clinical trial as front-line therapy.
One key strength of this study includes the large sample size provided by the NLSG study
dataset (N=2,343), which included detailed data on sex, ethnicity, age at diagnosis, diagnosis
subtype, and front-line therapy regimen. Another strength of this study is the sample
population represented over 100 distinct subtypes of lymphoma. Some subtypes may have
more clinical trials available than others, so analyzing a dataset with a wide variety of subtypes
may reduce this potential source of bias.
Several limitations exist within this study. First, this study was only conducted with
patients enrolled at one academic medical center in Omaha, Nebraska. It is possible that other
regions in the U.S. that have a different prevalence distribution of subtypes of lymphoma may
see different results for participating in registry studies and selecting a clinical trial as front-line
therapy. Previous literature has shown that patients who have had positive experiences with
clinical trials in their past are more willing to participate in future studies. This study did not
take into account whether the participants in the NLSG study had ever been previously offered
to participate in a clinical trial for their cancer, whether that be a non-interventional registry
study or an investigative therapeutic clinical trial. Additionally, the NLSG study database did not
have data available for whether its participants had ever previously been approached for
participation in a study for any other disease or condition other than their cancer. It is therefore
theoretically possible that some of the participants in this study may have had previously
participated in clinical research, which may skew their attitudes or beliefs positively about
participating in this study. This study also did not examine attitudes and behaviors of its
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participants towards participating in registry studies as well as clinical trials, which has been
previously shown to be significantly associated with participation. Another limitation of this
study is that clinical trials were not as ubiquitous in the early 1980s and 1990s as they are in
present-day. Some patients enrolled in the NLSG study at the beginning of the recruitment
period for the study may not have had any, or very few, clinical trials available to them,
whereas patients enrolled within the past year may have had several clinical trials available.
With the advent of the Internet, in particular clinicaltrials.gov, patients have much more
information available to them regarding the availability of clinical trials across the country, so
patients may be more likely to actively seek out care at institutions that offer therapies that are
currently involved within a clinical trial as they are able to research the trials in-depth at their
discretion. One last limitation that is of note is that the database did not collect information on
whether subsequent therapy regimens after the first-line therapy were clinical trials. It is
certainly possible that patients had enrolled in the NLSG study, selected an FDA-approved,
standard of care treatment first to treat their cancer and then elected to participate in a clinical
trial as a second- or third-line regimen. This study did not take this possibility into account,
however that may be of interest for future investigations.
Several recommendations are provided for future investigators. It may be beneficial for
similar research to be conducted in other cancer populations, as clinical trial participation may
vary widely depending on the type of cancer. The sample population in this study was
overwhelmingly White (91.5%), so it may be worthwhile to conduct further investigations
focusing on non-White populations such as Asian, Black, Hispanic, and Native American
populations. This study did not take into account the number of clinical trials that were
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available at different time points throughout the period where patients were enrolled into the
NLSG study. Repeated studies into populations that have been recruited into registry studies,
and subsequently offered clinical trial participation, within the past decade may be beneficial
due to the increase in number of clinical trials available nationwide. This study was conducted
at only one center in the Midwest U.S. There could be geographic differences in cancer
populations across the U.S. that were not accounted for in this study, and perhaps different
results would be found in more densely-populated metro areas with larger, more diverse
patient populations. Lastly, clinical trials are available for nearly every known disease;
therefore, more research is needed into factors associated with clinical trials across the disease
spectrum such as cardiovascular disease, diabetes, and respiratory diseases.

36

References

1. Center for Information and Study on Clinical Research Participation. (2013). Perceptions
& Insights study: Report on Study Participant Experiences. Retrieved
from https://www.ciscrp.org/download/2013-ciscrp-perceptions-and-insights-studyparticipant-experiences/?wpdmdl=4984
2. Centers for Disease Control and Prevention - United States Cancer Statistics: Data
Visualizations. (2015). Hodgkin lymphoma. Retrieved
from https://gis.cdc.gov/Cancer/USCS/DataViz.html
3. Centers for Disease Control and Prevention - United States Cancer Statistics: Data
Visualizations. (2015). Leukemia. Retrieved
from https://gis.cdc.gov/Cancer/USCS/DataViz.html
4. Centers for Disease Control and Prevention - United States Cancer Statistics: Data
Visualizations. (2015). Myeloma. Retrieved
from https://gis.cdc.gov/Cancer/USCS/DataViz.html
5. Centers for Disease Control and Prevention - United States Cancer Statistics: Data
Visualizations. (2015). Non-Hodgkin lymphoma. Retrieved
from https://gis.cdc.gov/Cancer/USCS/DataViz.html
6. Comis, R. L., Miller, J. D., Aldige, C. R., Krebs, L., & Stoval, E. (2003). Public attitudes
toward participation in cancer clinical trials. Journal of Clinical Oncology, 21(5), 830-835.
doi:10.1200/JCO.2002

37

7. Dehn, J., Arora, M., Spellman, S., et al. (2008). Unrelated donor hematopoietic cell
transplantation: factors associated with a better HLA match. Biol Blood Marrow
Transplant, 14(2), 1334-1340.
8. Dreyer, N.A., Garner, S. (2009). Registries for robust evidence. Journal of the American
Medical Association, 302(7), 790-791. doi:10.1001/jama.2009.1092
9. Dreyer, N.A., Tunis, S.R., Berger, M., et al. (2010). Why observational studies should be
among the tools used in comparative effectiveness research. Health Affairs, 29(10),
1818-1825. doi:10.1377/hlthaff.2010.0666 22
10. Friedberg, J.W., Taylor, M.D., Cerhan, J.R., Flowers, C.R., Dillon, H., Farber, C.M., . . ., &
Link, B.K. (2009). Follicular Lymphoma in the United States: First Report of the National
LymphoCare Study. Journal of Clinical Oncology, 27(8), 1202-1208.
doi:10.1200/JCO.2008.18.1495
11. Gliklich, R., Dreyer, N. A., Leavy, M. B., Velentgas, P., & Khurana, L. (2012). Standards in
the Conduct of Registry Studies for Patient-Centered Outcomes Research: A Guidance
Document for the Patient-Centered Outcomes Research Institute. Retrieved
from https://www.pcori.org/assets/Standards-in-the-Conduct-of-Registry-Studies-forPatient-Centered-Outcomes-Research.pdf
12. Gliklich, R.E., Dreyer, N.A. Registries for Evaluating Patient Outcomes: A User’s Guide.
2nd edition (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. d/b/a
Outcome] under Contract No. HHSA290200500351 TO3.) AHRQ Publication No.10EHC049. Rockville, MD: Agency for Healthcare Research and Quality. September 2010.

38

13. Green, M.R., Kihira, S., Long Liu, C.L., Nair, R.V., Salari, R., Gentles, A.J., . . ., & Alizadeh,
A.A. (2015). Mutations in early follicular lymphoma progenitors are associated with
suppressed antigen presentation. Proceedings of the National Academy of Sciences of
the United States of America, 112(10), E1116-E1125. doi:10.1073/pnas.1501199112.
14. Green, M.R., Vicente-Duenas, C., Romero-Camarero, I., Long Liu, C., Dai, B., GonzalezHerrero, I, . . . & Sanzhes-Garcia, I. (2014). Transient expression of Bcl6 is sufficient for
oncogenic function and induction of mature B-cell lymphoma. Nature Communications,
5, 3904. doi:10.1038/ncomms4904
15. Irving, M.J., Tong, A., Jan, S., Cass, A., Rose, J., Chadban, S., Allen, R.D., Craig, J.C., Wong,
G., & Howard, K. (2011). Factors that influence the decision to be an organ donor: a
systematic review of the qualitative literature. Nephrology Dialysis Transplantation,
27(6), 2526-2533. doi:10.1093/ndt/gfr683
16. Kaiser Health News. (2018, April 26 2018). 'Rapid Autopsy' Programs Seek Clues to
Cancer within Hours of Death. Kaiser Health News Retrieved
from https://khn.org/news/rapid-autopsy-programs-seek-clues-to-cancer-within-hoursof-death/
17. Kuppers, R. (2005). Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews
Cancer, 5(4), 251-262. doi:10.1038/nrc1589
18. Lopienski, K. (2014, Forte Research). Why Do Some Patients Enroll in Clinical Trials and
Others Don't? Retrieved from https://forteresearch.com/news/patients-enroll-clinicaltrials-others-dont/

39

19. Mallen, A. R., Boac, B. M., Todd, S., Robertson, S. E., Gandhi, A., Kuznicki, M., . . . Sook
Chon, H. (2018). Patient predictive factors for clinical trial participation. Journal of
Clinical Oncology, 36(15), 6530. doi:10.1200/JCO.2018.36.15_suppl.6530
20. Matten, M.R., Sliepcevich, E.M., Sarvela, P.D., Lacey, E.P., Woehlke, P.L., Richardson,
C.E., & Wright, W.R. (1991). Nurses’ knowledge, attitudes, and beliefs regarding organ
and tissue donation and transplantation. Public Health Reports, 106(2), 155-156.
21. Millar, T., Lerpiniere, C., Walker, R., & Smith, C. (2008). Postmortem tissue donation for
research: a positive opportunity? British Journal of Nursing, 17(10), 644-649.
doi:10.12968/bjon/2008.17.10.29479
22. Moorcraft, S. Y., Marriot, C., Peckitt, C., Cunningham, D., Chau, I., Starling, N., . . . Rao, S.
(2016). Patients' willingness to participate in clinical trials and their views on aspects of
cancer research: Results of a prospective patient survey. Trials, 17(17), 1105.
doi:10.1186/s13063-015-1105-3
23. Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004). Participation in cancer clinical
trials: Race-, sex-, and age-based disparities. Journal of the American Medical
Association, 291(22), 2720-2726. doi:10.1991/jama.291.22.2720
24. National Cancer Institute. (2015, February 9). What is Cancer? Retrieved
from https://www.cancer.gov/about-cancer/understanding/what-is-cancer
25. National Cancer Institute. (2018, April 27). Cancer Statistics. Retrieved
from https://www.cancer.gov/about-cancer/understanding/statistics

40

26. National Cancer Institute: Cancer Trends Progress Report. (2018, February). Financial
Burden of Cancer Care. Retrieved
from https://progressreport.cancer.gov/after/economic_burden
27. Research!America. (2013). National Poll on Clinical Research. Retrieved
from https://www.researchamerica.org/sites/default/files/uploads/June2013clinicaltrial
s.pdf
28. Rodriguez-Villar, C., Ruiz-Jaramillo, M.C., Paredes, D., Ruiz, A., Vilardell, J., & Manyalich,
M. (2007). Telephone consent in tissue donation: effectiveness and efficiency in
postmortem tissue generation. Transplantation Proceedings, 39(7), 2072-2075.
doi:10.1016/j.transproceed.2007.07.004
29. Solomon, D. H., Shadick, N. A., Weinblatt, M. E., Frits, M., Iannaccone, C., Zak, A., &
Korzenik, J. R. (2017). Clinical patient registry recruitment and retention: A survey of
patients in two chronic disease registries. BMC Medical Research Methodology, 17(59)
doi:10.1186/s12874-017-0343-3
30. Switzer, G. E., Bruce, J. G., Myaskovsky, L., DiMartini, A., Shellmer, D., Confer, D. L., . . .
Dew, M. A. (2013). Race and ethnicity in decisions about unrelated hematopoietic stem
cell donation. Blood, 121, 1469-1476. doi:10.1182/blood-2012-06-437343
31. Tandon, R., Verma, K., Vanathi, M., Pandey, R., & Vajpayee, R. (2004). Factors affecting
eye donation from postmortem cases in a tertiary care hospital. Cornea, 23(6), 597-601.
doi:10.1097/01.jco.0000121706.58571.f6
32. Tejeda, H. A., Green, S. B., Trimble, E. L., Ford, L., High, J. L., Ungerleider, R. S., . . .
Brawley, O. W. (1996). Representation of african-americans, hispanics, and whites in
41

national cancer institute cancer treatment trials. Journal of the National Cancer
Institute, 88(12), 812-816.
33. Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016). Role of clinical trial participation in
cancer research: Barriers, evidence, and strategies. American Society of Clinical
Oncology Educational Book, 35, 185-198. doi:10.14694/EDBK_156686
34. University of Nebraska Medical Center. (2018). About Us. Retrieved
from https://www.unmc.edu/aboutus/index.html
35. University of Nebraska Medical Center. (2018). The Fred & Pamela Buffett Cancer
Center: About Us. Retrieved
from https://www.unmc.edu/cancercenter/about/index.html
36. University of Nebraska Medical Center. (2018). Mission & Values. Retrieved
from https://www.unmc.edu/aboutus/history/index.html
37. University of Nebraska Medical Center. (2018). Nebraska Lymphoma Study Group.
Retrieved from https://www.unmc.edu/intmed/divisions/onchem/patientcare/lymphoma/nlsg.html
38. Wakefield, C.E., Reid, J., & Homewood, J. (2011). Religious and ethnic influences on
willingness to donate organs and donor behavior: an Australian perspective. Progress in
Transplantation, 21(2), 161-168. doi:10.1177/152692481102100213

42

Service Learning/Capstone Experience Reflections
My experience with my placement site, the University of Nebraska Medical Center, was
one of the experiences of my educational career. UNMC is committed to furthering the
education of not only those in the state of Nebraska, but of those across the U.S. As I have been
an employee at UNMC for over four years, I knew a great amount about UNMC prior to starting
my education and prior to starting my Service Learning & Capstone Experience (SL/CE) projects.
One of the key aspect that I learned more about was the collaboration between investigators at
UNMC. In the development of our rapid autopsy program, I collaborated frequently with a basic
scientist, Dr. Paul Grandgenett, who oversees the Pancreatic Rapid Autopsy Program (PRAP) at
UNMC, to learn about how their program was started, how they currently run their program,
and what their goals are for the future. In addition to collaborating with Dr. Grandgenett, I
worked weekly with my committee preceptor, Dr. Matt Lunning, to provide updates on how the
program development was progressing. He provided great insight to the clinical and
pathological aspects of how a rapid autopsy program for patients with hematologic
malignancies should be run. Some other individuals that I collaborated with include Emily Gale,
who assists with the Nebraska Lymphoma Study Group program, as she was a great resource
for the IRB application process and the informed consent form (ICF) development.
One aspect that I was different than what I expected when I started the project was the
rate at which new projects at UNMC are developed. I anticipated that we would move much
faster than we were able to, but quickly found out that collaboration across many different
departments and professionals takes a tremendous amount of effort, and perhaps more
importantly, time. I now have a much better understanding as to the amount of work that is
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required to start new programs or even improve upon existing programs at UNMC, and
therefore also have a much greater appreciation for the programs that currently exist.
Some of the SL/CE activities have been highlighted previously. Throughout the
semester, I spent time during the regular business day, as well as evenings, working through a
list of activities that Dr. Lunning and I developed together. A few of the key activities that were
performed include: submission of an IRB application, including an informed consent form, to
UNMC’s IRB. This submission alone took nearly 40 hours of work, as a great deal amount of
collaboration with other UNMC professionals was required. Other SL/CE activities that were
performed include meeting with Dr. Grandgenett on a few different occasions to discuss how
the PRAP program was started back in the 1990s, how the program has progressed over the
past few decades, how the program currently functions, and what the program’s goals are for
the future. I shadowed Dr. Grandgenett for a few hours to learn how they order supplies, how
they prepare several “autopsy carts” so that they are ready for up to three autopsies at a time,
and what the process is like for tissue sample preparation after the autopsy is completed and
how the samples are stored for future use by investigators. Another major activity that was
performed was an extensive literature review on existing autopsy programs across the U.S. and
U.K. to learn about some of they key aspects of their programs. This literature review, along
with the knowledge learned from Dr. Grandgenett, set the foundation for our autopsy program.
Lastly, some other activities that were performed include the development of a presentation
for key stakeholders at UNMC about our proposed program, the development of pre-, during-,
and post-autopsy checklists, and the start of the development of a clinical database for linking
key clinical data and pathological tissue samples.
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As stated above, a presentation for UNMC stakeholders was developed. This
presentation is important because high-level administrators at the university need to be
informed of the importance of a rapid autopsy program for this patient population as well as
the enormous potential impact on future scientific research for investigators at the university.
The checklists were developed in a similar manner to those of the PRAP group as theirs were
clear and easy to follow. Additionally, the IRB application was developed according to UNMC’s
IRB guidelines. The clinical database is still under development and a final product has not been
achieved. The sustainability plan is still in progress as how to continue to track data.
Some of my greatest contributions to the SL activities were the IRB application, the
creation of the autopsy checklists, the ongoing development of the clinical database, and the
development of a presentation for UNMC stakeholders. One of my greatest accomplishments,
which goes hand-in-hand as a strength, was my ability to manage my time along with several
different aspects of this project at the same time. Another consideration is that I consider
myself a “part-time” student in the MPH program as I maintain full-time employment at UNMC.
Not only was I focusing a great amount of energy and detail to my SL/CE projects, but I was
maintaining my focus on my employment as well.
One of the biggest challenges that I faced was the need to collaborate with several
different professionals at UNMC. Though it is a great pleasure to work with many great people
at UNMC, it was difficult to work around everyone’s schedules to schedule meetings. Another
challenge was balancing my time between work and the SL/CE activities. I was able to
overcome these challenges because I had a great support system at home with my wife and my
family members who were able to take care of many different responsibilities outside of work
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and school. Another way I was able to overcome some of these challenges was staying late at
UNMC’s campus several nights per week as well as spending countless hours on the weekend in
the UNMC computer lab working on SL/CE activities, in particular my statistical analysis.
My views of public health practice have been greatly impacted by my experience with
the SL/CE project. Throughout my MPH education in the College of Public Health, I have had to
collaborate with other students on class projects every semester. These collaborations gave me
good practice for future collaborations in more of a “real world” setting. One view that has
changed since the start of my SL/CE project is realizing the amount of hard work and
collaboration that is required for a new program to be successfully developed. A new program
could take several months, perhaps even over a year, to be properly developed, even with fulltime commitment to the development of the program. One view of public health practice that
has stayed the same is knowing that, despite the hard work and countless hours spent towards
new or ongoing initiatives, public health professional’s efforts are worthwhile as they have the
potential to positively impact the lives of the others in their communities, across the country, or
even across the world.
The only ethical issues that were required to be addressed were managed through the
IRB application for the rapid autopsy program. The IRB provides oversight, including ethical
oversight, for all research involving humans or human biological material (HBM) at UNMC.
Another ethical issue that was identified in the development of the project was the process of
approaching a patient regarding discussing the possibility of participating in the rapid autopsy
program. It was appropriately decided that the physicians and nurse program coordinators
included on the IRB application would be responsible for approaching eligible patients. This was
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decided as the best course of action because they have extensive experience with approaching
patients for other clinical trials at UNMC and have navigated difficult situations with patients
who are nearing the end of their lives before.
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